IMRX: Immuneering Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 57.53
Enterprise Value ($M) 12.32
Book Value ($M) 57.72
Book Value / Share 1.95
Price / Book 1.00
NCAV ($M) 44.42
NCAV / Share 1.50
Price / NCAV 1.29

Profitability (mra)
Return on Invested Capital (ROIC) -0.94
Return on Assets (ROA) -0.51
Return on Equity (ROE) -0.56

Liquidity (mrq)
Quick Ratio 7.99
Current Ratio 7.99

Balance Sheet (mrq) ($M)
Current Assets 55.26
Assets 68.56
Liabilities 10.84
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
4 days ago 13G/A Cormorant Asset Management, LP 0.00 -100.00
4 days ago 13G/A Citadel Advisors Llc 0.00
04-10 13G/A Price T Rowe Associates Inc /md/ 3.10 -73.05
04-05 13G/A BlackRock, Inc. 4.70 -34.34
03-27 13G/A Merrin Investors LLC 9.46 15.17
01-16 13G/A Zeskind Benjamin J. 12.60 5.47

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 137,427 355,999 38.60
2024-11-14 429,996 1,369,338 31.40
2024-11-13 89,977 287,933 31.25
2024-11-12 86,549 218,190 39.67

(click for more detail)

Similar Companies
HRMY – Harmony Biosciences Holdings, Inc. HROW – Harrow, Inc.
IKNA – Ikena Oncology, Inc. INAB – IN8bio, Inc.
IOVA – Iovance Biotherapeutics, Inc.


Financial data and stock pages provided by
Fintel.io